Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 10/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 5/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31208560 | 0.82 | NTSR2 (0.55) | RENNTSR2NMUR2NMUR1NTSR1 | |
| SCHEMBL30248935 | 0.80 | REN (0.52) | RENNTSR2NMUR2NMUR1NTSR1 | |
| SCHEMBL1661256 | 0.80 | NMUR2 (0.54) | RENNMUR2NMUR1 | |
| SCHEMBL29673326 | 0.80 | NTSR2 (0.63) | RENNTSR2NTSR1SORT1 | |
| SCHEMBL13599743 | 0.79 | KDM1A (0.55) | RENNTSR2NMUR2NMUR1KDM1A | |
| SCHEMBL31362679 | 0.79 | SLC6A2 (0.56) | REN | |
| SCHEMBL30862339 | 0.79 | REN (0.49) | RENNTSR2NMUR2NMUR1KDM1A | |
| SCHEMBL30862340 | 0.79 | REN (0.49) | RENNTSR2NMUR2NMUR1KDM1A | |
| SCHEMBL16899839 | 0.78 | MAPK8 (0.46) | RENNTSR2NTSR1SORT1 | |
| SCHEMBL30368311 | 0.78 | REN (0.58) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | REN 2640/4885NTSR2 441/4885NMUR2 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.